Supplements · Metabolic & Cardiometabolic
coenzyme Q10 decreases blood pressure
In plain terms: Does CoQ10 lower blood pressure?
Part of: 🧪 coenzyme Q10
Contested—older small trials say yes but a Cochrane review and newer trials found no reliable effect, so it's not a dependable blood-pressure treatment.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Genuinely contested. Older/smaller trials and a GRADE dose-response MA (26 RCTs, n=1831; SBP −4.77 mmHg in cardiometabolic disease, U-shaped optimum ~100–200 mg/day) point to a modest reduction — but the disconfirming evidence is substantial: a Cochrane review judged the trials unreliable/insufficient, a controlled-hypertension RCT with 24-h ambulatory BP found no effect, and healthy…
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Hosseini Roknabadi SM, Abolhassani A, Davoodi E, Moghaddam Rad FZ, Jafarnejad S 2025 · Inflammopharmacology | observational | supports | low | Narrative review of mechanistic pathways (antioxidant, anti-inflammatory, eNOS, arterial stiffness) by which CoQ10 may lower BP; states clinical trials 'suggest' CoQ10 may lower SBP/DBP in essential hypertension, mostly as adjunctive therap |
| Zhao D, Liang Y, Dai S, Hou S, Liu Z, Liu M, Dong X, Zhan Y, Tian Z, Yang Y 2022 · Adv Nutr | meta-analysis | supports | moderate | GRADE dose-response MA (26 RCTs, n=1831): SBP -4.77 mmHg in cardiometabolic disease; U-shaped, 100-200 mg/d optimal; GRADE moderate (SBP), lower for DBP. |
| Burke BE, Neuenschwander R, Olson RD 2001 · South Med J | RCT | supports | moderate | Double-blind RCT (isolated systolic hypertension, n=83): oral CoQ10 lowered systolic BP vs placebo. |
| Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF 2009 · J Hypertens | RCT | contradicts | low | 2x2 factorial double-blind RCT, 85 nondiabetic CKD 3-4 patients (74 completed), CoQ10 200 mg/d and/or omega-3 4 g/d for 8 wk: 'omega3FA, but not CoQ, reduced 24-h ambulatory heart rate (P<0.0001) and blood pressure (P<0.0001)'; 'CoQ had no independent effect on blood pressure but increased heart rate.' A null on this directional claim, so contradicts; near-normotensive CKD population, no CoQ10 estimate in abstract. |
| Karimi M, Pirzad S, Hooshmand F, Shirsalimi N, Pourfaraji SMA 2025 · Int J Cardiol Cardiovasc Risk Prev | meta-analysis | mixed | moderate | SR/MA of CoQ10 on BP and heart rate in adults: prior results inconsistent; effect on BP/HR not consistently significant across populations. |
| Li Y, El-Sehrawy AAMA, Shankar A, Srivastava M, Mohammed JS, Hjazi A, Singh M, Sapaev IB, Mustafa YF, Abosaoda MK 2025 · Clin Ther | meta-analysis | mixed | moderate | SR/MA in T2D: CoQ10 effects on lipid profile and BP suggested but not uniformly significant. |
| Rosenfeldt F, Hilton D, Pepe S, Krum H 2003 · Biofactors | meta-analysis | supports | low | SR of 8 hypertension trials: mean SBP -16 / DBP -10 mmHg with CoQ10 (older, small trials). QUALITY DOWNGRADED moderate->low 2026-07-22: pre-GRADE synthesis of small trials whose pooled effect is ~3x the -4.77 mmHg found by the 2022 GRADE dose-response MA (26 RCTs, n=1831), and Cochrane independently judged this trial base unreliable/insufficient. Classic small-study/publication-bias signature. |
| Porta DJ, Pasqualini ME, Juncos LI, Carranza D, Mukdsi JH, Rivoira MA, García NH 2026 · The Journal of nutritional biochemistry | animal | supports | moderate | Uninephrectomized Wistar rats on high-sodium diet; CoQ10 200 mg/kg/day prevented BP rise vs. high-sodium-only group (128±2.8 vs 119.2±3.7 mmHg, P<0.05), via preserved pressure-natriuresis and reduced oxidative stress. |
| Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, Nicholls MG, Scott RS, George PM 2012 · Am J Hypertens | RCT | contradicts | moderate | Crossover RCT (metabolic syndrome, 24-h ambulatory BP): CoQ10 did NOT significantly reduce blood pressure. |
| Shah SA, Sander S, Cios D, Lipeika J, Kluger J, White CM 2007 · Ann Pharmacother | RCT | contradicts | low | RCT in healthy individuals: no significant hemodynamic/BP effect of CoQ10 (and no QTc prolongation). |
| Ho MJ, Li EC, Wright JM 2016 · Cochrane Database Syst Rev | meta-analysis | contradicts | moderate | Cochrane review (primary hypertension): trials unreliable/insufficient — uncertain that CoQ10 lowers BP; no clinically significant effect established. |
| Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS 1999 · J Hum Hypertens | RCT | supports | moderate | Double-blind RCT (hypertension + CAD): CoQ10 60 mg bid lowered SBP/DBP and improved insulin/glucose vs B-vitamin control. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.